| Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review JM Sanders, ML Monogue, TZ Jodlowski, JB Cutrell Jama 323 (18), 1824-1836, 2020 | 3418 | 2020 |
| Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model ML Monogue, M Tsuji, Y Yamano, R Echols, DP Nicolau Antimicrobial agents and chemotherapy 61 (11), 10.1128/aac. 01022-17, 2017 | 87 | 2017 |
| Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model IM Ghazi, ML Monogue, M Tsuji, DP Nicolau International Journal of Antimicrobial Agents 51 (2), 206-212, 2018 | 47 | 2018 |
| In Vitro Discordance with In Vivo Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New … ML Monogue, LM Abbo, R Rosa, JF Camargo, O Martinez, RA Bonomo, ... Antimicrobial agents and chemotherapy 61 (7), 10.1128/aac. 00486-17, 2017 | 47 | 2017 |
| Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa ML Monogue, DP Nicolau Journal of Antimicrobial Chemotherapy 73 (4), 942-952, 2018 | 46 | 2018 |
| In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam–β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance … ML Monogue, S Giovagnoli, C Bissantz, C Zampaloni, DP Nicolau Antimicrobial agents and chemotherapy 62 (9), 10.1128/aac. 02596-17, 2018 | 45 | 2018 |
| Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa IM Ghazi, ML Monogue, M Tsuji, DP Nicolau Pharmacology 101 (5-6), 278-284, 2018 | 43 | 2018 |
| Population pharmacokinetics and safety of ceftolozane-tazobactam in adult cystic fibrosis patients admitted with acute pulmonary exacerbation ML Monogue, RS Pettit, M Muhlebach, JJ Cies, DP Nicolau, JL Kuti Antimicrobial agents and chemotherapy 60 (11), 6578-6584, 2016 | 43 | 2016 |
| Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms ML Monogue, AK Thabit, Y Hamada, DP Nicolau Antimicrobial agents and chemotherapy 60 (8), 5001-5005, 2016 | 43 | 2016 |
| In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model ML Monogue, J Tabor-Rennie, K Abdelraouf, DP Nicolau Antimicrobial agents and chemotherapy 63 (7), 10.1128/aac. 00233-19, 2019 | 28 | 2019 |
| Optimizing antibiotic dosing strategies for the treatment of gram-negative infections in the era of resistance ML Monogue, JL Kuti, DP Nicolau Expert review of clinical pharmacology 9 (3), 459-476, 2016 | 28 | 2016 |
| Efficacy of humanized cefiderocol exposures over 72 hours against a diverse group of Gram-negative isolates in the neutropenic murine thigh infection model SM Stainton, ML Monogue, M Tsuji, Y Yamano, R Echols, DP Nicolau Antimicrobial agents and chemotherapy 63 (2), 10.1128/aac. 01040-18, 2019 | 27 | 2019 |
| Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo AK Thabit, ML Monogue, DP Nicolau Antimicrobial agents and chemotherapy 60 (8), 5072-5075, 2016 | 27 | 2016 |
| Comparative assessment of tedizolid pharmacokinetics and tissue penetration between diabetic patients with wound infections and healthy volunteers via in vivo microdialysis SM Stainton, ML Monogue, A Baummer-Carr, AK Shepard, JF Nugent, ... Antimicrobial agents and chemotherapy 62 (1), 10.1128/aac. 01880-17, 2018 | 26 | 2018 |
| Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia ML Monogue, JK Ortwine, W Wei, K Eljaaly, KP Bhavan Journal of Infection and Public Health 11 (5), 727-731, 2018 | 24 | 2018 |
| Tedizolid vs linezolid for the treatment of nontuberculous mycobacteria infections in solid organ transplant recipients YK Poon, RM La Hoz, LS Hynan, J Sanders, ML Monogue Open Forum Infectious Diseases 8 (4), ofab093, 2021 | 22 | 2021 |
| Pharmacokinetics-pharmacodynamics of β-lactamase inhibitors: are we missing the target? ML Monogue, DP Nicolau Expert Review of Anti-Infective Therapy 17 (8), 571-582, 2019 | 22 | 2019 |
| Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic … AK Thabit, ML Monogue, JV Newman, DP Nicolau International Journal of Antimicrobial Agents 51 (5), 727-732, 2018 | 18 | 2018 |
| Pharmacokinetics and tissue penetration of ceftolozane-tazobactam in diabetic patients with lower limb infections and healthy adult volunteers ML Monogue, SM Stainton, A Baummer-Carr, AK Shepard, JF Nugent, ... Antimicrobial agents and chemotherapy 61 (12), 10.1128/aac. 01449-17, 2017 | 18 | 2017 |
| Physical compatibility of fosfomycin for injection with select iv drugs during simulated Y-site administration ML Monogue, SS Almarzoky Abuhussain, JL Kuti, DP Nicolau The Bulletin of the American Society of Hospital Pharmacists 75 (1), e36-e44, 2018 | 13 | 2018 |
